Importantly, the synergism between CHK1 inhibition and inhibition of PI3K pathway components has been observed also in triple-negative breast cancer (TNBC) cell lines with mutations in PI3K, PTEN, plus p5337, and extends to high-grade serous ovarian carcinoma38. This evidence concerns the gene CHEK1 and triple-negative breast carcinoma.